Co-Diagnostics, Inc. (ticker: CODX) is an NASDAQ-listed clinical biotech company. DredgeCap's structured extraction of CODX's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. CODX reported $146K in revenue and -$9.14M for the period ending 2026-03-31, with operating cash flow of -$7.85M. Cash and equivalents stood at $8.23M (up 332.5% year-over-year). Total assets of $21.50M exceed total liabilities of $5.46M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
CODX Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Co-Diagnostics, Inc. (CODX) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.